Dr Shereef Elmoamly
Qualifications
MB.BCh, Msc, MD, MRCP, FRCPath
GMC number: 7189434
Practising since: 2001
Specialties
Haematology
Consultation times
- Saturday morning
- Overview
About
Dr Shereef Elmoamly is a Consultant Haematologist at Russell’s Hall Hospital, where he has worked since 2020. He completed his specialist training in the West Midlands after a clinical fellowship at Manchester Royal Infirmary, and he went on to complete an MD focused on blood cancers and blood clots.
He is the Chemotherapy Lead for The Dudley Group NHS Foundation Trust. His main areas of interest are general blood disorders, cancer of the blood and bone marrow, and venous thrombosis.
Dr Elmoamly cares for a large number of patients each week, both in the outpatient clinic and on the ward. He treats conditions such as anaemia, clotting and bleeding problems, blood cancers, and patients who need bone marrow transplant care. He also works in the laboratory, interpreting blood films and bone marrow samples.
He is actively involved in clinical research, taking part in several haemato‑oncology trials as a principal investigator or co‑investigator, and he has published widely in medical journals.
Dr Elmoamly also carries out the following procedures:
Bone marrow aspirate and trephine
Venesection
Chemotherapy
Blood transfusion
Special interests
• Haemochromatosis
Languages spoken
English
Treatments and tests offered by Dr Shereef Elmoamly at Nuffield Health
- Haemato-oncology
- Venesection
- Haematology profiles
Locations Dr Shereef Elmoamly works with
Related experience
Research
- MSc degree in Internal Medicine; Thesis title: Multitransfusion and Ferrokinetics in Cases with Myelodysplastic Syndrome with Special Emphasis on Cardiac Functions.
- MSc degree in Clinical Haematology; Essay title: Epigenetics in haematologic disorders and role of epigenetic modifiers as targeted therapy of haematologic malignancies.
- MD degree; Thesis title: Incidence of Venous Thromboembolism (VTE) in patients with Haematological Malignancies and Relation to laboratory biomarkers.
Publications including (full list can be found on https://www.researchgate.net/profile/Shereef-Elmoamly )
-Elmoamly, S., Obici, L. (2022). Amyloidosis: Pathogenesis, Types, and Diagnosis. In: Ragab, G., Quartuccio, L., Goubran, H. (eds) Paraproteinemia and Related Disorders. Springer, Cham.
- Elmoamly S, Mattar M, Yacoub M F, & Afif A. Can Biomarkers of Coagulation, Platelet Activation, and Inflammation Predict Venous Thromboembolism in Patients with Haematological Malignancies? Acta haematol, 2019; 141:245-253. (DOI: 10.1159/000496914).
-Murthy V, Kapuge N, Kartsios C, Ewing J, Xenou E, Kaparou M, Elmoamly S, Nikolousis E; Azacitidine Improves Outcome in Patients with MDS and AML with High Risk Cytogenetics - a Single Center Experience. Blood 2018; 132 (Supplement 1): 5529. doi: https://doi.org/10.1182/blood-2018-99-109774
- Elmoamly S & Afif A. Can biomarkers of coagulation, platelet activation, and inflammation predict mortality in patients with haematological malignancies? Hematology. 2018: 23:2, 89-95. (DOI: 10.1080/10245332.2017.1365458).
Memberships
- Royal College of Pathologists
- Royal College of Physicians
- British Society of Haematology
- British medical association
Other posts held
- Consultant Haematologist at Dudley Group NHS Foundation Trust
Insurers Dr Shereef Elmoamly works with
Dr Shereef Elmoamly works with the following private medical insurance providers:
- Aviva Health
- AXA Health
- Bupa
- Police Mutual
- Vitality Health (Pru Health)
Declaration
Dr Shereef Elmoamly does not hold a share or financial interest in this hospital, another Nuffield Health hospital or the company.
Dr Shereef Elmoamly does not have a share or financial interest in equipment used at this hospital or another Nuffield Health hospital.
Dr Shereef Elmoamly does not hold any paid advisory role(s) at this hospital or on behalf of Nuffield Health.